Skip to Main Content
Home Books Quick Answers: Pharmacy

Hepatitis B (HBV)

  • Sections
  • Print
  • Get Citation

    Citation

    Disclaimer: These citations have been automatically generated based on the information we have and it may not be 100% accurate. Please consult the latest official manual style if you have any questions regarding the format accuracy.

    AMA Citation
    Hepatitis B (HBV). In: Roller LK, Baumgartner L, Desselle SP. Roller L.K., & Baumgartner L, & Desselle S.P.(Eds.),Eds. Lauren K. Roller, et al.eds. Quick Answers: Pharmacy. McGraw-Hill; Accessed July 10, 2020. https://accesspharmacy.mhmedical.com/content.aspx?bookid=2735&sectionid=228233446
    APA Citation
    Hepatitis b (hbv). Roller LK, Baumgartner L, Desselle SP. Roller L.K., & Baumgartner L, & Desselle S.P.(Eds.),Eds. Lauren K. Roller, et al. (2019). Quick Answers: Pharmacy. McGraw-Hill. https://accesspharmacy.mhmedical.com/content.aspx?bookid=2735&sectionid=228233446
    MLA Citation
    "Hepatitis B (HBV)." Quick Answers: Pharmacy Roller LK, Baumgartner L, Desselle SP. Roller L.K., & Baumgartner L, & Desselle S.P.(Eds.),Eds. Lauren K. Roller, et al. McGraw-Hill, 2019, https://accesspharmacy.mhmedical.com/content.aspx?bookid=2735&sectionid=228233446.

    Download citation file:

    RIS (Zotero)
    EndNote
    BibTex
    Medlars
    ProCite
    RefWorks
    Reference Manager
    Mendeley
    © Copyright
  • Tools
  • Search Book
  • Clip
Top

SOURCE

Source: Deming P. Viral hepatitis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. New York, NY: McGraw-Hill; 2017. http://accesspharmacy.mhmedical.com/content.aspx?bookid=1861&sectionid=132516044. Accessed April 10, 2017.

DEFINITION

  • Acute or chronic viral infection of liver.

  • Associated with development of:

    • Chronic cirrhosis.

    • Hepatocellular carcinoma (HCC)

ETIOLOGY

  • DNA virus, Hepadnaviridae family.

PATHOPHYSIOLOGY

  • Virion attaches to hepatocyte cell surface receptors and replicates.

  • HBV is not pathogenic to cells.

    • Immune response to virus cytotoxic to hepatocytes.

    • Destruction of heptocytes releases alanine transaminase (ALT), thus increasing levels.

  • Liver attempts to regenerate in environment of persistent inflammation, resulting in cirrhosis.

  • HCC develops after years of inflammatory processes provoked by ongoing HBV infection.

EPIDEMIOLOGY

  • Infection transmitted through activities that involve percutaneous or mucosal contact with infectious blood or body fluids.1

    • Parenterally (injection drug use; needle sticks, or sharp instrument exposures)

    • Perinatally.

    • Sexually.

PREVENTION AND SCREENING

  • Prophylaxis with:

    • HBV vaccine for active immunity (Tables 1 and 2)

    • Hepatitis B immune globulin (HBIG) for temporary passive immunity in postexposure cases2

  • Common vaccine side effects include (lasting ~1–2 days)3

    • Soreness at injection site (3–29% most common)4

    • Fever (1–6% most common)4

    • Headache.

    • Fatigue.

    • Irritability.

  • Immunization goals:

    • Prevention of short-term viremia to limit:

      • Transmission of infection.

      • Clinical disease.

      • Chronic HBV infection.

TABLE 1.Recommendations for Hepatitis B Virus (HBV) Vaccination
View Table|Favorite Table|Download (.pdf)
TABLE 1. Recommendations for Hepatitis B Virus (HBV) Vaccination

Infants—within 24 hours of birth.

Adolescents, including all previously unvaccinated children <19 years old.

All unvaccinated adults at risk for infection:

  • Sexual exposure.

    • Sex partners of HBsAg-positive persons.

    • Sexually active persons not in mutually monogamous relationship.

    • Persons seeking evaluation/treatment for STI

    • MSM

  • Percutaneous or mucosal exposure to blood.

    • Recent/current uses of injection drugs.

    • Household contacts of HBsAg-positive persons.

    • Residents and staff of facilities for developmentally disabled persons.

    • Incarcerated.

    • Healthcare and public safety workers.

    • Age <60 with diabetes mellitus.

    • Age ≥60 with diabetes mellitus at discretion of treating clinician.

  • Chronic liver disease, including but not limited to.

    • Hepatitis C virus infection.

    • Cirrhosis.

    • Fatty liver disease.

    • Alcoholic liver disease.

    • Autoimmune hepatitis.

    • ALT or AST level >2x upper limit of normal.

  • Adults with ESRD, including those in predialysis care, with hemodialysis, peritoneal dialysis, or home dialysis.

  • Adults with HIV infection.

  • Pregnant women at risk for HBV infection.

    • More than one sex partner in previous 6 months.

    • Previously evaluated for STI

    • Recent or current injection drug use.

    • HBsAg-positive sex partner.

  • International travelers to regions with high or intermediate levels of endemic HBV infection.

  • Adults in following settings:

    • STI treatment facilities.

    • HIV testing and treatment facilities.

    • Drug-abuse treatment and prevention facilities.

    • Healthcare settings targeting services to persons who inject drugs.

    • Correctional facilities.

    • Healthcare settings ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

This site uses cookies to provide, maintain and improve your experience. MHE Privacy Center Close